−8.5184USD
−37.88 MUSD
2.20 MUSD
12.49 M
About Seelos Therapeutics, Inc.
Sector
Industry
CEO
Raj Mehra
Website
Headquarters
New York
Employees (FY)
16
Founded
1987
ISIN
US81577F2083
FIGI
BBG000BZ9N90
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the development of products that address significant unmet needs in Central Nervous System (CNS) disorders and other rare disorders. The company was founded by Raj Mehra in 1987 and is headquartered in New York, NY.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of SEEL is 0.39 USD — it has decreased by 10.55% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Seelos Therapeutics, Inc. stocks are traded under the ticker SEEL.
Seelos Therapeutics, Inc. is going to release the next earnings report on Apr 26, 2024. Keep track of upcoming events with our Earnings Calendar.
SEEL earnings for the last quarter are −3.60 USD whereas the estimation was −1.81 USD which accounts for −98.68% surprise. Estimated earnings for the next quarter are −0.80 USD. See more details about Seelos Therapeutics, Inc. earnings.
Seelos Therapeutics, Inc. revenue for the last quarter amounts to 0 USD despite the estimated figure of 0 USD. In the next quarter revenue is expected to reach 202.00 K USD.
Yes, you can track Seelos Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, SEEL shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Seelos Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 16, 2024, the company has 16.00 employees. See our rating of the largest employees — is Seelos Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Seelos Therapeutics, Inc. EBITDA is −40.44 M USD, and current EBITDA margin is −1.84 K%. See more stats in Seelos Therapeutics, Inc. financial statements.